Accueil / À propos / Gouvernance / Comité pour l’Équité, la Diversité et l’Inclusion

Comité pour l’Équité, la Diversité et l’Inclusion

Le Comité pour l'Équité, la Diversité et l'Inclusion facilite le développement et le maintien de partenariats collaboratifs au sein de GlycoNet pour créer une communauté dans laquelle les membres du groupe sont représentés et participent équitablement à tous les niveaux. Le Comité travaille à la mise en œuvre du plan d’équité, de diversité et d’inclusion du Réseau et à la sensibilisation à l’inclusion au sein de GlycoNet.

Le mandat du Comité pour l’EDI a été approuvé par le Conseil d'Administration le 8 juillet 2020. Lisez le message suivant du Président du Comité pour l’EDI:

Les organisations qui adoptent avec succès les principes d'équité, de diversité et d'inclusion (EDI) améliorent leur créativité, leur productivité et leurs produits. Le conseil d'administration de GlycoNet croit que, si nous, en tant que communauté, soutenons l'équité, la diversité et l'inclusion, nous améliorerons l'innovation et les résultats de la recherche au sein du réseau. En conséquence, le conseil d'administration a établi le comité pour l’EDI, qui comprend des représentants de l'ensemble de la communauté GlycoNet et rapporte directement au conseil d'administration. Son mandat consiste globalement à recommander des actions et des programmes qui permettront d'améliorer l'EDI dans l'ensemble du réseau. Veuillez lire le document sur les termes de référence et la politique d’EDI de GlycoNetet initier des discussions avec vos collègues sur ce que l'EDI signifie pour vous.


Nils O. Petersen,
Président, Comité pour l’EDI
Vice-président, Conseil d'Administration

Membres du Comité

Dr. Bohlmann holds academic appointments in the Department of Botany, the Department of Forest and Conservation Sciences, and is an Associate of the UBC Wine Research Centre. He is co-director of the UBC Genome Science and Technology (GSAT) graduate program. His research deals with the molecular biochemistry and biology of plant secondary metabolites, genomics of conifers, grapevines, and various medicinal plants, and plant defense against insects.

With more than 20 years of international experience in both the academic and private sectors, Catalina Lopez-Correa’s deep understanding of genomics and innovation has inspired leaders in science and industry to collaborate toward solving some of the world’s greatest challenges.

Before taking on her role as Chief Scientific Officer in July 2021, she served as Executive Director of the Canadian COVID-19 Genomics Network (CanCOGeN).

Dr. Petersen is a Fellow of the Chemical Institute of Canada. He currently serves as a member of three boards of not-for-profit organizations including Compute Canada, TECTERRA, and the Canadian Light Source (CLS) for which he is Chair of the Board. He recently finished terms as a member of the boards of ArboraNano, a Business-led NCE, the California Nanosystems Institute (CNSI), and the Pacific Institute for Mathematical Sciences, and as Chair of the Board of NSERC’s Strategic Network program BiopSys at the University of Toronto.

Norma has extensive experience over a 28-year career with Merck in Sales, Marketing, Strategic Planning, Corporate Affairs, Pharmacoeconomics, Health Education and Training, Government Relations, Operations and Policy and Patient Access. Most recently she was involved in developing and management of key partnerships for Merck in Health Information Technology, and Health Data Science along with Life Sciences Accelerators/Research collaborations.


Dr. Sipione is a professor in the Department of Pharmacology and in the Neuroscience and Mental Health Institute at the University of Alberta. She is also a member of the Group on the Molecular and Cellular Biology of Lipids at the University of Alberta. Dr. Sipione is a biochemist and a neurobiologist with a long-standing interest in neurodegeneration, Huntington’s disease (HD) and the role of lipids in the brain.

Joshua bw

Joshua Kofsky is a PhD candidate in the Capicciotti Lab at Queen’s University. He completed a BSc in Chemistry at Queen’s University in 2020 with an undergraduate thesis project on the chemical synthesis of O-glycans. His current research focuses on new ways to access defined O-glycan structures through chemoenzymatic synthesis and extraction of glycans from natural sources.


Dr. Wakarchuk is a Professor from the Department of Biological Sciences at the University of Alberta. The Wakarchuk lab investigates the structure and function of the enzymes which make and degrade various glycoconjugates. This work has been enabling the chemo-enzymatic synthesis of bioactive glycoconjugates both in the laboratory and for industrial projects. The Wakarchuk lab has expertise with both mammalian and bacterial carbohydrate active enzymes for glycan remodelling applications.


Dr. Willis’ research group leverages glycobiology, microbiology, and immunology to address fundamental questions regarding the pivotal roles of glycans in human immune systems. Specifically, she is investigating how glycans are involved in population-specific autoimmune diseases, such as lupus, scleroderma, and rheumatoid arthritis. Her research group also studies the function of bacterial protein glycosylation and its influence on cellular homeostasis and environmental sensing in the microbiome.



Elizabeth is the CEO of GlycoNet. She was involved in the GlycoNet initiative since the Letter of Intent stage and served as the Associate Director, Business for the Alberta Glycomics Centre from 2007–2015. Prior to her position with the Centre, she worked as a manager of large-scale and multi-institutional projects with Genome Prairie. In addition to her PhD in biochemistry, Elizabeth has an MBA in biotechnology management.

Termes de Référence

Voir les Termes de Référence (PDF)

Des nouvelles du comité

Novembre 2021

Réseau Canadien de la Glycomique
E5-33 Gunning/Lemieux Chemistry Centre
University of Alberta, T6G 2G2
Tél.: 780-492-6204
Téléc.: 780-492-4147

Subscribe to GlycoNet’s Newsletter

© Réseau Canadien de la Glycomique (GlycoNet). Tous droits réservés.

Scroll to Top